Pharma Pulse 6/24/25: Building Patient Centricity into Clinical Trial Software from Day One; Industry Voices on Current Pricing and Reimbursement Models

2025 DIA Annual Meeting: Building Patient Centricity into Clinical Trial Software from Day One

In an interview with Applied Clinical Trials, Brian Ongioni, chief product officer, uMotif, discussed how the company integrates patient and site feedback from the earliest stages of software development to create intuitive, regulatory-ready digital health tools that reduce burden and improve usability—highlighting co-design strategies, real-world trial examples, and the growing role of AI in advancing patient-reported outcomes.

Industry Voices on Current Pricing and Reimbursement Models

In a Pharmaceutical Executive Peer Exchange, panelists Edward Ahn, Rob Philo, and Shana Gunderson Hua—moderated by Ed Schoonveld—shared insights on recent policy changes, including upcoming Medicare Part D updates, and explored how clinical trial design, pricing, and reimbursement models are evolving to meet both FDA standards and payer expectations.

Five Steps to Ensure Accurate 340B Program Data

To maintain compliance and maximize the benefits of the 340B Drug Pricing Program, hospitals and health systems must proactively monitor data accuracy, swiftly address errors with third-party administrators, and implement safeguards to prevent recurring issues—ensuring continued support for vulnerable patient populations through improved medication access and resource optimization.

Q&A: Supporting Pharmacy Technicians Through Daily Recognition

In a recent Q&A with Drug Topics, Taylor Watterson, PharmD, PhD, emphasized that simple, everyday gestures—such as saying thank you, encouraging breaks, recognizing certifications, and advocating for fair treatment—can go a long way in valuing pharmacy technicians, boosting morale, and improving retention in pharmacy settings.

Real-World Data Help to Inform Treatment Selection in Metastatic Urothelial Carcinoma

Real-world data continue to support the use of enfortumab vedotin plus pembrolizumab and avelumab maintenance therapy in metastatic urothelial carcinoma, with insights from recent studies helping clinicians such as Amit Mehta individualize treatment based on patient characteristics—such as age, comorbidities, metastatic patterns, and biomarkers—while also informing toxicity management, therapy sequencing, and the broader application of trial findings to everyday practice.